title: The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover.
abstract: OBJECTIVE
  Pathogen reduction technologies (PRT) for platelets are now compatible with both plasma and platelet additive solutions (PAS). The aim of this study was to examine the effect of PRT on the platelet storage lesion, in the presence of PAS with low plasma carryover.
  
  
  METHODS
  PRT-treated (Mirasol) and untreated buffy coat-derived platelet concentrates prepared in 28% plasma/PAS-IIIM were evaluated using in vitro cell quality parameters on days 1, 2, 5, and 7 post-collection.
  
  
  RESULTS
  At day 5, there were no significant differences between control and PRT treated platelets for swirl, viability, pO(2) , pCO(2) , mean platelet volume and adenosine diphosphate-induced aggregation. PRT treatment did not affect the functional integrity of the mitochondria. However, PRT resulted in a decrease in pH and enhancement of platelet glycolysis and activation, evidenced by increased glucose consumption and lactate production rates, increased expression of CD62P, CD63, annexin V staining and increased secretion of cytokines (P < 0.05). Hypotonic shock response and aggregation in response to collagen were also significantly reduced in PRT treated platelets (P < 0.05).
  
  
  CONCLUSIONS
  Despite the observed differences in platelet metabolism and activation observed following PRT treatment in PAS and low plasma carryover, the results suggest that treatment and storage of platelets in PAS is no more detrimental to platelets than treatment and storage in plasma.
authors.affiliation: Research and Business Development, Australian Red Cross Blood Service, Sydney, NSW, Australia.
authors.forename: L
authors.initials: L
authors.lastname: Johnson
authors.forename: K M
authors.initials: KM
authors.lastname: Winter
authors.forename: S
authors.initials: S
authors.lastname: Reid
authors.forename: T
authors.initials: T
authors.lastname: Hartkopf-Theis
authors.forename: S
authors.initials: S
authors.lastname: Marschner
authors.forename: R P
authors.initials: RP
authors.lastname: Goodrich
authors.forename: D C
authors.initials: DC
authors.lastname: Marks
mesh_terms: D016824:Antigens, Human Platelet / Q000378:metabolism; D001792:Blood Platelets / Q000166:cytology* / Q000378:metabolism*; D001793:Blood Preservation; D058731:Blood Safety / Q000379:methods*; D004203:Disinfection / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009997:Osmotic Pressure; D019999:Pharmaceutical Solutions / Q000494:pharmacology; D010949:Plasma; D010974:Platelet Aggregation / Q000187:drug effects; D013997:Time Factors
chemical_list: D016824:Antigens, Human Platelet; D019999:Pharmaceutical Solutions